Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Ting Tsung Chang"'
Autor:
Massimo Puoti, Graham Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, SamS Lee, Rui Marinho, Jean-Francois DuFour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Ran Liu, Tami Pilot-Matias, Federico Mensa
Publikováno v:
Journal of Virus Eradication, Vol 3, Iss , Pp 33- (2017)
Externí odkaz:
https://doaj.org/article/d8fdec303da142a0aa0afbed4e240667
Autor:
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 3, Pp 375-387 (2024)
Background/Aims Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokineti
Externí odkaz:
https://doaj.org/article/ed2aee832b8041db91c2040ffaf8a503
Autor:
Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 2, Pp 191-205 (2024)
Background/Aims Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week tr
Externí odkaz:
https://doaj.org/article/aeead632d03142ec95bc4b04123f5c17
Autor:
Selena Y. Lin, Wei Xia, Amy K. Kim, Dion Chen, Shelby Schleyer, Lin Choi, Zhili Wang, James P. Hamilton, Harry Luu, Hie-Won Hann, Ting-Tsung Chang, Chi-Tan Hu, Abashai Woodard, Terence P. Gade, Ying-Hsiu Su
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract An optimized hepatocellular carcinoma (HCC)-targeted methylation next generation sequencing assay was developed to discover HCC-associated methylation markers directly from urine for HCC screening. Urine cell-free DNA (ucfDNA) isolated from
Externí odkaz:
https://doaj.org/article/97ab82d66331480894a625b29cff3494
Autor:
Kai-Ching Hsiao, Siou-Ying Ruan, Shih-Min Chen, Tai-Yu Lai, Ren-Hao Chan, Yan-Ming Zhang, Chien-An Chu, Hung-Chi Cheng, Hung-Wen Tsai, Yi-Fang Tu, Brian K. Law, Ting-Tsung Chang, Nan-Haw Chow, Chi-Wu Chiang
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Protein phosphatase 2A (PP2A) is one of the major protein phosphatases in eukaryotic cells and is essential for cellular homeostasis. PP2A is a heterotrimer comprising the dimeric AC core enzyme and a highly variable regulatory B
Externí odkaz:
https://doaj.org/article/bdf89f1ff45c4c4d8f505cd5ca76658d
Autor:
Young-Suk Lim, Henry L.Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L.A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Publikováno v:
JHEP Reports, Vol 5, Iss 10, Pp 100847- (2023)
Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in p
Externí odkaz:
https://doaj.org/article/6fa5ef22c05d4c2b921cc10c1111b3f7
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Backgrounds: Hepatitis B virus (HBV) biomarkers reflect the status of HBV infection; however, their role in patients with chronic hepatitis B and C (HBV/HCV) coinfection remains unknown. This study evaluated the characteristics of HBV biomar
Externí odkaz:
https://doaj.org/article/ffe6d6a5f4b545de91071be512b18d0b
Autor:
Wai Kay Seto, Ting-Tsung Chang, Abhijit Chowdhry, Chi-Yi Chen, Mustafa Kemal Celen, Xiaoli Ma, Mang Ma, Ajay Duseja, Ki Tae Yoon, Wan Cheng Chow, Leland Yee, Gregor Weber, Ms Jin Youn, John F. Flaherty, Anuj Gaggar, Bing Gao, Gregory Camus, Eric Bassetti, Jae Seok Hwang, Tetshuro Inokuma, Young- Suk Lin, Edward J. Gane
Publikováno v:
Annals of Hepatology, Vol 28, Iss , Pp 100905- (2023)
Introduction and Objectives: Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-b
Externí odkaz:
https://doaj.org/article/ff618283cb6f44cfa2d42ed8f0d2ea63
Autor:
JinlinHou, Gane, Edward, Balabanska, Rozalina, WenhongZhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Komolmit, Piyawat, Leerapun, Apinya, Zenghui Xue, Chen, Ethan, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang
Publikováno v:
Clinical & Molecular Hepatology; Apr2024, Vol. 30 Issue 2, p191-205, 22p
Autor:
Ting‐Tsung Chang, Ji‐Hong Cheng, Hung‐Wen Tsai, Kung‐Chia Young, Sun‐Yuan Hsieh, Cheng‐Hsun Ho
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 5, Iss 3, Pp 199-212 (2019)
Abstract Hepatobiliary cancer is the third leading cause of cancer death worldwide. Appropriate markers for early diagnosis, monitoring of disease progression, and prediction of postsurgical outcome are still lacking. As the majority of circulating N
Externí odkaz:
https://doaj.org/article/97d6fbeca62b4d46b2cd6811bdb685ab